#26 Practical RWE – Data Retention and Archiving

 

Data retention and archiving in non-interventional studies (NIS) are foundational practices that support the integrity of the scientific process, comply with regulatory requirements, facilitate future research, serve educational purposes, and ensure ethical management of study data. These practices are essential for advancing knowledge, fostering innovation, and ultimately improving health outcomes.

In many jurisdictions, regulatory bodies mandate the retention of research data for a specified period (see below).

Argentina = 2 years
Austria = 15 years
Brazil = 5 years
Germany = 10 years
Japan = 5 years
Netherlands = 15 years
South Korea = 3 years
Turkey = 5 years

Pain Point #1 = Most countries don’t define how long you should retain NIS  documents. In these cases, we recommend you defer (refer) to IPSE GPP data retention guidance = At least 5 years after final report or first publication of study results.

Pain Point #2 = Trying to force your non-interventional (observational)  study documents into a filing system designed specifically for clinical trials. There is a (reasonably) simple solution for this.  Use the real world study document index that was developed from the TMF Reference Model by NIS experts who were keen to mitigate this pain.

CDISC Real World Study Document Index: https://www.cdisc.org/sites/default/files/2023-09/Real_World_Studies_Document_Index_v1_2020_07_29.xlsx

CDISC TMF Reference Model: https://www.cdisc.org/tmf

In conclusion, through adherence to established guidelines and the utilization of resources like the CDISC Real World Study Document Index, researchers can navigate the complexities of data retention, thereby contributing to the broader goals of enhancing knowledge, spurring innovation, and improving global health outcomes.

Share this story...
UK – NICE – RWE Framework

October 14, 2023|2023, RWE 201|

RWE 201 - UK – NICE – RWE Framework  NICE RWE Framework: https://www.nice.org.uk/corporate/ecd9/chapter/overviewReal-world data (RWD) encompasses various types of information on patient health, care delivery, and experiences collected outside [...]

UK – MHRA – Randomised Controlled Trials Using Real World Data

October 14, 2023|2023, RWE 201|

RWE 201 - UK – MHRA – Randomised Controlled Trials Using Real World Data   MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions The MHRA guideline focuses on sponsors planning to [...]

UK – MHRA – Use of RWD to Support Regulatory Decisions

October 14, 2023|2023, RWE 201|

RWE 201 - UK – MHRA – Use of RWD to Support Regulatory Decisions   MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions The MHRA (Medicines and Healthcare products Regulatory Agency) [...]

Real World Evidence (RWE) 201 – France – Haute Autorité de Santé (HAS) – Real World Study Guide

September 4, 2023|2023, RWE 201|

RWE 201 - France – Haute Autorité de Santé (HAS) – Real World Study Guide  HAS Real World Stidy Guide: https://www.has-sante.fr/upload/docs/application/pdf/2021-06/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdfThe Haute Autorité de Santé (HAS), France's National Authority [...]